Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ability to regenerate damaged tissue is one of the great challenges in biomaterials and medicine. Successful treatments will require advances in areas ranging from basic cell biology to materials synthesis, but there have been major hurdles in translating the biomedical advances, such as scaffolds that direct stem cell differentiation, into marketed products. Careful consideration of the challenges going from bench to bedside is paramount in maximizing the chances that a good idea becomes a good treatment. We look at a variety of material-based platforms that have made it into the clinic, from biodegradable polymers for wound healing to organs grown ex vivo, and how they have been able to navigate the scientific, regulatory, and business hurdles into the market place.

Original publication




Journal article


Sci Transl Med

Publication Date





Animals, Biocompatible Materials, Cell Differentiation, Humans, Materials Testing, Models, Biological, Polymers, Regenerative Medicine, Stem Cells, Tissue Engineering, United States, United States Food and Drug Administration